References
Vaz I, Kumar A, Shariff M, Doshi R. Comment on: Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease. Am J Cardiovasc Drugs. 2020. https://doi.org/10.1007/s40256-020-00412-2.
Fu Y, Zhu W, Zhou Y, Chen H, Yan L, He W. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Am J Cardiovasc Drugs. 2020;20:139–47. https://doi.org/10.1007/s40256-019-00369-x.
Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, Wu LS, Kuo CF, Kuo CT, See LC. Efectiveness and safety of nonvitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019;8(5):e011112.
Lee S-R, Lee H-J, Choi E-K, Han K-D, Jung J-H, Cha M-J, Oh S, Lip GYH. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019;73(25):3295–308.
Douros A, Azoulay L, Yin H, Suissa S, Renoux C. Non-vitamin K antagonist oral anticoagulants and risk of serious liver injury. J Am Coll Cardiol. 2018;71(10):1105–13.
Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL, Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017;103(11):834–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No external funds were used in preparing this reply.
Conflict of interest
Yonghui Fu, Wengen Zhu, Yue Zhou, He Chen, Lan Yan, and Wenfeng He declare that they have no potential conflicts of interest that might be relevant to this reply.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Code availability
Not applicable.
Rights and permissions
About this article
Cite this article
Fu, Y., Zhu, W., Zhou, Y. et al. Author’s Reply to Vaz et al.: “Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease”. Am J Cardiovasc Drugs 20, 507–508 (2020). https://doi.org/10.1007/s40256-020-00413-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-020-00413-1